What's new in bullous pemphigoid

Journal of Dermatology

Volumn 37, Issue 3, 2010, Pages 194-204

  Ujiie, Hideyuki ^a   Shibaki, Akihiko ^a   Nishie, Wataru ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Animal model; Humanized; Immunoglobulin E autoantibody; Passive transfer; Type XVII collagen (COL17)

Indexed keywords

AUTOANTIBODY; COLLAGEN TYPE 17 ANTIBODY; EPITOPE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

BULLOUS PEMPHIGOID; COMPLEMENT ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MAST CELL DEGRANULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENICITY; REVIEW;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIBODIES; BLISTER; COLLAGEN TYPE XVIII; COMPLEMENT ACTIVATION; EPIDERMIS; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MAST CELLS; MICE; MODELS, ANIMAL; NEUTROPHIL INFILTRATION; PEMPHIGOID, BULLOUS; RABBITS;

EID: 77649220734     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00792.x     Document Type: Review

References (46)

1. Bernard P, Vaillant L, Labeille B et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995 131 : 48 52.
2. Marazza G, Pham HC, Scharer L et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009 161 : 861 868.
3. Stanley JR, Hawley-Nelson P, Yuspa SH et al. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981 24 : 897 903.
4. Stanley JR, Tanaka T, Mueller S et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988 82 : 1864 1870.
5. Guo L, Degenstein L, Dowling J et al. Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell 1995 81 : 233 243.
6. Thoma-Uszynski S, Uter W, Schwietzke S et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 2004 122 : 1413 1422.
7. Skaria M, Jaunin F, Hunziker T et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230. J Invest Dermatol 2000 114 : 998 1004.
8. Hall RP III., Murray JC, McCord MM et al. Rabbits immunized with a peptide encoded for by the 230-kD bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 1993 101 : 9 14.
9. Kiss M, Husz S, Janossy T et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005 24 : 1 10.
10. Diaz LA, Ratrie H III., Saunders WS et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990 86 : 1088 1094.
11. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992 99 : 243 250.
12. Hopkinson SB, Riddelle KS, Jones JC. Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J Invest Dermatol 1992 99 : 264 270.
13. Bedane C, McMillan JR, Balding SD et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997 108 : 901 907.
14. Ishiko A, Shimizu H, Kikuchi A et al. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J Clin Invest 1993 91 : 1608 1615.
15. Nonaka S, Ishiko A, Masunaga T et al. The extracellular domain of BPAG2 has a loop structure in the carboxy terminal flexible tail in vivo. J Invest Dermatol 2000 115 : 889 892.
16. Giudice GJ, Emery DJ, Zelickson BD et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993 151 : 5742 5750.
17. Zillikens D, Rose PA, Balding SD et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997 109 : 573 579.
18. Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol 1998 139 : 365 370.
19. Zillikens D, Mascaro JM, Rose PA et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997 109 : 679 683.
20. Dopp R, Schmidt E, Chimanovitch I et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000 42 : 577 583.
21. Haase C, Budinger L, Borradori L et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 1998 110 : 282 286.
22. Sitaru C, Schmidt E, Petermann S et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002 118 : 664 671.
23. Tsuji-Abe Y, Akiyama M, Yamanaka Y et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2005 37 : 145 149.
24. Bernard P, Reguiai Z, Tancrede-Bohin E et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009 145 : 537 542.
25. Hofmann S, Thoma-Uszynski S, Hunziker T et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002 119 : 1065 1073.
26. Anhalt GJ, Diaz LA. Animal models for bullous pemphigoid. Clin Dermatol 1987 5 : 117 125.
27. Sams WM Jr., Gleich GJ. Failure to transfer bullous pemphigoid with serum from patients. Proc Soc Exp Biol Med 1971 136 : 1027 1031.
28. Anhalt GJ, Labib RS, Voorhees JJ et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982 306 : 1189 1196.
29. Liu Z, Diaz LA, Troy JL et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993 92 : 2480 2488.
30. Liu Z, Giudice GJ, Swartz SJ et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995 95 : 1539 1544.
31. Chen R, Ning G, Zhao ML et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001 108 : 1151 1158.
32. Liu Z, Giudice GJ, Zhou X et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997 100 : 1256 1263.
33. Olasz EB, Roh J, Yee CL et al. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J Invest Dermatol 2007 127 : 2807 2817.
34. Lanschuetzer CM, Olasz EB, Lazarova Z et al. Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy. J Invest Dermatol 2009 129 : 1203 1207.
35. Nishie W, Sawamura D, Goto M et al. Humanization of autoantigen. Nat Med 2007 13 : 378 383.
36. Wang G, Ujiie H, Shibaki A et al. Blockade of autoantibody-initiated tissue damage by using recombinant Fab antibody fragments against pathogenic autoantigen. Am J Pathol 2010 (in press).
37. Nishie W, Sawamura D, Natsuga K et al. A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies. J Immunol 2009 183 : 4088 4093.
38. Liu Z, Sui W, Zhao M et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008 31 : 331 338.
39. Provost TT, Tomasi TB Jr. Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol 1974 18 : 193 200.
40. Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999 29 (Suppl 3 109 112.
41. Dimson OG, Giudice GJ, Fu CL et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003 120 : 784 788.
42. Iwata Y, Komura K, Kodera M et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008 144 : 41 48.
43. Dresow SK, Sitaru C, Recke A et al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009 160 : 429 432.
44. Zone JJ, Taylor T, Hull C et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007 127 : 1167 1174.
45. Fairley JA, Burnett CT, Fu CL et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007 127 : 2605 2611.
46. Fairley JA, Baum CL, Brandt DS et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009 123 : 704 705.